-
Something wrong with this record ?
Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study
J. Marschall, G. Fejer, P. Lempe, L. Prochazkova, M. Kuchar, K. Hajkova, M. van Elk
Language English Country United States
Document type Journal Article, Randomized Controlled Trial
- MeSH
- Depression drug therapy MeSH
- Adult MeSH
- Double-Blind Method MeSH
- Emotions drug effects MeSH
- Hallucinogens administration & dosage pharmacology MeSH
- Cross-Over Studies MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Surveys and Questionnaires MeSH
- Psilocybin administration & dosage pharmacology MeSH
- Anxiety drug therapy MeSH
- Dose-Response Relationship, Drug MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Randomized Controlled Trial MeSH
BACKGROUND: Microdoses of psychedelics (i.e. a sub-hallucinogenic dose taken every third day) can reduce symptoms of depression, anxiety and stress according to anecdotal reports and observational studies. Research with medium to high doses of psilocybin points towards potential underlying mechanisms, including the modulation of emotion and interoceptive processing. AIMS: In this preregistered study, we investigated whether psilocybin microdoses alter self-reported interoceptive awareness and whether repeated microdosing over 3 weeks modulates emotion processing and reduces symptoms of anxiety and depression. METHODS: We used a double-blind, placebo-controlled, within-subject crossover design. Participants completed the Multidimensional Assessment of Interoceptive Awareness Questionnaire 11⁄2 h after self-administering their second dose (or placebo), and the emotional go/no-go task and the shortened Depression Anxiety Stress Scale 11⁄2 h after self-administering their seventh dose. RESULTS: Our confirmatory analyses revealed that psilocybin microdosing did not affect emotion processing or symptoms of anxiety and depression compared with placebo. Our exploratory analyses revealed that psilocybin microdosing did not affect self-reported interoceptive awareness, that symptoms of depression and stress were significantly reduced in the first block compared with baseline, that participants broke blind in the second block and that there was no effect of expectations. Further research in a substance-naïve population with clinical range anxiety and depressive symptoms is needed to substantiate the potential beneficial effects of microdosing.
Department of Experimental Neurobiology National Institute of Mental Health Klecany Czech Republic
Department of Psychology Leiden University Leiden The Netherlands
Department of Psychology University of Amsterdam Amsterdam The Netherlands
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22011523
- 003
- CZ-PrNML
- 005
- 20220506130615.0
- 007
- ta
- 008
- 220425s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1177/02698811211050556 $2 doi
- 035 __
- $a (PubMed)34915762
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Marschall, Josephine $u Department of Psychology, University of Amsterdam, Amsterdam, The Netherlands
- 245 10
- $a Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study / $c J. Marschall, G. Fejer, P. Lempe, L. Prochazkova, M. Kuchar, K. Hajkova, M. van Elk
- 520 9_
- $a BACKGROUND: Microdoses of psychedelics (i.e. a sub-hallucinogenic dose taken every third day) can reduce symptoms of depression, anxiety and stress according to anecdotal reports and observational studies. Research with medium to high doses of psilocybin points towards potential underlying mechanisms, including the modulation of emotion and interoceptive processing. AIMS: In this preregistered study, we investigated whether psilocybin microdoses alter self-reported interoceptive awareness and whether repeated microdosing over 3 weeks modulates emotion processing and reduces symptoms of anxiety and depression. METHODS: We used a double-blind, placebo-controlled, within-subject crossover design. Participants completed the Multidimensional Assessment of Interoceptive Awareness Questionnaire 11⁄2 h after self-administering their second dose (or placebo), and the emotional go/no-go task and the shortened Depression Anxiety Stress Scale 11⁄2 h after self-administering their seventh dose. RESULTS: Our confirmatory analyses revealed that psilocybin microdosing did not affect emotion processing or symptoms of anxiety and depression compared with placebo. Our exploratory analyses revealed that psilocybin microdosing did not affect self-reported interoceptive awareness, that symptoms of depression and stress were significantly reduced in the first block compared with baseline, that participants broke blind in the second block and that there was no effect of expectations. Further research in a substance-naïve population with clinical range anxiety and depressive symptoms is needed to substantiate the potential beneficial effects of microdosing.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a úzkost $x farmakoterapie $7 D001007
- 650 _2
- $a klinické křížové studie $7 D018592
- 650 _2
- $a deprese $x farmakoterapie $7 D003863
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a emoce $x účinky léků $7 D004644
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a halucinogeny $x aplikace a dávkování $x farmakologie $7 D006213
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a psilocybin $x aplikace a dávkování $x farmakologie $7 D011562
- 650 _2
- $a průzkumy a dotazníky $7 D011795
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Fejer, George $u Department of Psychology, University of Amsterdam, Amsterdam, The Netherlands $1 https://orcid.org/0000000249045504
- 700 1_
- $a Lempe, Pascal $u Department of Psychology, University of Amsterdam, Amsterdam, The Netherlands
- 700 1_
- $a Prochazkova, Luisa $u Department of Psychology, Leiden University, Leiden, The Netherlands $1 https://orcid.org/0000000279923603 $7 xx0234560
- 700 1_
- $a Kuchar, Martin $u Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Prague, Czech Republic $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic $1 https://orcid.org/0000000276166352 $7 xx0070908
- 700 1_
- $a Hajkova, Katerina $u Forensic Laboratory of Biologically Active Substances, Department of Chemistry of Natural Compounds, University of Chemistry and Technology Prague, Prague, Czech Republic $u Department of Experimental Neurobiology, National Institute of Mental Health, Klecany, Czech Republic
- 700 1_
- $a van Elk, Michiel $u Department of Psychology, University of Amsterdam, Amsterdam, The Netherlands $1 https://orcid.org/0000000276313551
- 773 0_
- $w MED00152742 $t Journal of psychopharmacology (Oxford, England) $x 1461-7285 $g Roč. 36, č. 1 (2022), s. 97-113
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34915762 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506130607 $b ABA008
- 999 __
- $a ok $b bmc $g 1789233 $s 1162721
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 36 $c 1 $d 97-113 $e 20211217 $i 1461-7285 $m Journal of psychopharmacology $n J Psychopharmacol $x MED00152742
- LZP __
- $a Pubmed-20220425
